Literature DB >> 11804619

Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex.

Klaus Fink1, David J Dooley, Wolfgang P Meder, Nirmala Suman-Chauhan, Sandra Duffy, Hans Clusmann, Manfred Göthert.   

Abstract

Gabapentin and pregabalin (S-(+)-3-isobutylgaba) produced concentration-dependent inhibitions of the K(+)-induced [Ca(2+)](i) increase in fura-2-loaded human neocortical synaptosomes (IC(50)=17 microM for both compounds; respective maximal inhibitions of 37 and 35%). The weaker enantiomer of pregabalin, R-(-)-3-isobutylgaba, was inactive. These findings were consistent with the potency of these drugs to inhibit [(3)H]-gabapentin binding to human neocortical membranes. The inhibitory effect of gabapentin on the K(+)-induced [Ca(2+)](i) increase was prevented by the P/Q-type voltage-gated Ca(2+) channel blocker omega-agatoxin IVA. The alpha 2 delta-1, alpha 2 delta-2, and alpha 2 delta-3 subunits of voltage-gated Ca(2+) channels, presumed sites of gabapentin and pregabalin action, were detected with immunoblots of human neocortical synaptosomes. The K(+)-evoked release of [(3)H]-noradrenaline from human neocortical slices was inhibited by gabapentin (maximal inhibition of 31%); this effect was prevented by the AMPA receptor antagonist NBQX (2,3-dioxo-6-nitro-1,2,3,4-tetrahydro[f]quinoxaline-7-sulphonamide). Gabapentin and pregabalin may bind to the Ca(2+) channel alpha 2 delta subunit to selectively attenuate depolarization-induced Ca(2+) influx of presynaptic P/Q-type Ca(2+) channels; this results in decreased glutamate/aspartate release from excitatory amino acid nerve terminals leading to a reduced activation of AMPA heteroreceptors on noradrenergic nerve terminals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11804619     DOI: 10.1016/s0028-3908(01)00172-1

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  117 in total

Review 1.  Calcium channel alpha2delta subunits: differential expression, function, and drug binding.

Authors:  Norbert Klugbauer; Else Marais; Franz Hofmann
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

Review 2.  Prophylactic migraine therapy: mechanisms and evidence.

Authors:  Nabih M Ramadan
Journal:  Curr Pain Headache Rep       Date:  2004-04

Review 3.  P/Q-type calcium channel modulators.

Authors:  V Nimmrich; G Gross
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

4.  The analgesic effect of pregabalin in patients with chronic pain is reflected by changes in pharmaco-EEG spectral indices.

Authors:  Carina Graversen; Søren S Olesen; Anne E Olesen; Kristoffer Steimle; Dario Farina; Oliver H G Wilder-Smith; Stefan A W Bouwense; Harry van Goor; Asbjørn M Drewes
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

Review 5.  [Pregabalin and postoperative hyperalgesia. A review].

Authors:  A J Lederer; H Bornemann-Cimenti; M Wejbora; C Kern-Pirsch; K Michaeli; A Sandner-Kiesling
Journal:  Schmerz       Date:  2011-02       Impact factor: 1.107

Review 6.  Road map for pain management in pancreatic cancer: A review.

Authors:  Marie José Lahoud; Hampig Raphael Kourie; Joelle Antoun; Lana El Osta; Marwan Ghosn
Journal:  World J Gastrointest Oncol       Date:  2016-08-15

Review 7.  Pregabalin: as adjunctive treatment of partial seizures.

Authors:  Greg Warner; David P Figgitt
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

8.  Influence of aminophylline on the anticonvulsive action of gabapentin in the mouse maximal electroshock seizure threshold model.

Authors:  J J Luszczki; K Jankiewicz; M Jankiewicz; S J Czuczwar
Journal:  J Neural Transm (Vienna)       Date:  2007-08-24       Impact factor: 3.575

9.  Effects of pregabalin in patients with hypnotic-dependent insomnia.

Authors:  Youg Won Cho; Mei Ling Song
Journal:  J Clin Sleep Med       Date:  2014-05-15       Impact factor: 4.062

Review 10.  Pharmaceutical treatment options for fibromyalgia.

Authors:  Leslie J Crofford
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.